Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
Rhea-AI Summary
Profusa (Nasdaq: PFSA) entered a know-how agreement with Mayo Clinic on Feb. 12, 2026 to investigate high-impact clinical applications of its Lumee™ continuous tissue oxygen monitoring technology.
The collaboration targets potential U.S. commercialization for critical limb ischemia and new tethered products across cardiovascular, renal, multi-organ, and orthopedic indications. Profusa cites over $100 million invested in Lumee development; Mayo Clinic holds a financial interest and will use any revenue to support its mission.
Positive
- Signed know-how agreement with Mayo Clinic (Feb. 12, 2026)
- Targeting U.S. commercialization of Lumee for critical limb ischemia
- $100 million+ invested in Lumee development to date
- Multiple clinical indications targeted: cardiovascular, renal, multi-organ, orthopedic
Negative
- No regulatory approval yet for new Lumee indications
- Commercial outcome uncertain despite collaboration and investment
- Mayo Clinic financial interest may create perceived conflicts
News Market Reaction – PFSA
In the Feb 13 session, PFSA declined 33.44%, reflecting a significant negative market reaction. Argus tracked a peak move of +23.5% during that session. Argus tracked a trough of -42.0% from its starting point during tracking. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.0x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Reverse stock split | Negative | -36.4% | 1-for-75 reverse split reducing outstanding shares; shares fell sharply. |
| Jan 29 | Clinical data update | Positive | -3.4% | Positive US pilot study results for Lumee oxygen sensor and revenue outlook. |
| Jan 16 | Product launch | Positive | +4.1% | Launch of Lumee tissue oxygen Healthcare Research offering and RUO kits. |
| Jan 08 | Customer addition | Positive | +0.1% | Leading Greek vascular surgeon adopts Lumee Oxygen for practice and studies. |
| Dec 31 | Distribution deal | Positive | -14.0% | French Lumee Oxygen distributor MedSell and long-term revenue targets announced. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive commercial and clinical news has often met mixed or negative next-day price reactions, while capital-structure actions like the reverse split aligned with sharp declines.
Over the past few months, Profusa focused on building the Lumee™ Oxygen franchise and shoring up its capital structure. It expanded European distribution via MedSell targeting roughly 200,000 EU CLI cases annually and added key vascular KOLs in Greece. It launched Lumee tissue oxygen Healthcare Research offerings and presented positive US pilot clinical data, while guiding to initial revenues in 2026–2027. A 1-for-75 reverse split on Feb 9, 2026 coincided with a steep selloff. The Mayo Clinic collaboration extends this commercialization and clinical-application push in oxygen monitoring.
Key Terms
continuous tissue oxygen monitoring medical
critical limb ischemia medical
postoperative perfusion monitoring medical
biochemistry medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product
Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications
BERKELEY, Calif, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to enable the continuous monitoring of an individual’s biochemistry, has entered into a know-how agreement with Mayo Clinic. The collaboration entails investigation of high impact clinical applications of Profusa’s oxygen monitoring technologies for new product development and commercialization. Potential target indications include cardiovascular, renal, multi-organ, and orthopedic applications, among others, where intra-organ postoperative perfusion monitoring has potential to improve clinical outcomes. The collaboration also supports Profusa’s potential commercialization of Lumee oxygen sensing and tissue monitoring technology for critical limb ischemia in the U.S.
Michael Kendrick, M.D., Chair of Department of Surgery at Mayo Clinic, Rochester, Minn., said, “Oxygen is essential for cellular metabolism and tissue repair, with lack of sufficient oxygenation impairing wound healing, increasing risk of infection, and contributing to complications common to surgery, such as leakage and anastomotic structure. Our collaboration gives us the opportunity to leverage their innovative platform to potentially address unmet clinical challenges, including the ability to monitor beyond subcutaneous tissue.”
“Following more than a decade of development and over
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Contacts
Investor and Media Contacts
email: info@coreir.com
phone: 1 (212) 655-0924
